Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Bill Number

S. 1717

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-05-12: Read twice and referred to the Committee on Finance.

Last Updated

2026-06-11T12:33:38Z

AI-Generated Summary

Purpose

The Ensuring Patient Access to Critical Breakthrough Products Act of 2025 aims to speed up Medicare coverage for innovative medical devices that receive priority review from the Food and Drug Administration (FDA). It creates a temporary "transitional" period during which these devices are generally covered under Medicare, reducing delays in access for patients while allowing time for full coverage decisions.

Key Provisions

• Definition of Breakthrough Devices: A "breakthrough device" is a medical device (as defined under FDA rules) that the Secretary of Health and Human Services (HHS) designates if it qualifies for priority review under FDA's breakthrough device program. This designation process begins 18 months after the law's enactment.
• Transitional Coverage Period: For designated breakthrough devices, Medicare must provide coverage for 4 years starting from the designation date, unless the device is used outside its FDA-approved instructions or poses an unreasonable risk of harm based on clinical data review.
• Designation Process: Device manufacturers can apply for breakthrough status for FDA-cleared, classified, or approved devices. HHS must decide within 6 months, providing an explanation if denied. Annual reports to Congress will detail applications, designations, and denials.
• National Coverage Determinations (NCDs): If a request for a formal Medicare coverage decision (NCD) on a breakthrough device is submitted at least 9–12 months before the end of the transitional period, HHS must issue a final decision before the period ends.
• Funding: Allocates $10 million annually from 2026 through 2031 to the Centers for Medicare & Medicaid Services (CMS) to implement these changes.

Significant Changes to Existing Law

• Amends Section 1862(a)(1) of the Social Security Act to add a new exception to Medicare's general rule against covering unproven items or services, specifically mandating coverage for breakthrough devices during the 4-year transitional period (with limited exceptions).
• Adds new definitions in Section 1861(nnn) for "breakthrough device" and "transitional coverage period."
• Introduces a new Section 1899C in Part E of Title XVIII, establishing the designation process tied to FDA priority review criteria.
• Modifies Section 1862(l)(2) to require timely NCD decisions for breakthrough devices, addressing delays in the current Medicare coverage process where innovative devices can face years of uncertainty.

Potential Impacts

• On Government Agencies: Increases administrative workload for CMS and HHS, including reviewing applications, making designations, and expediting NCDs. The dedicated funding helps offset costs but may strain resources if application volumes are high.
• On Citizens: Medicare beneficiaries (primarily seniors and people with disabilities) gain faster access to cutting-edge medical devices, potentially improving health outcomes and treatment options without waiting for lengthy coverage reviews.
• On International Relations: Minimal direct impact, though it could indirectly encourage global medical device innovation by making the U.S. market more attractive for FDA-approved products.
• Broader Effects: May accelerate adoption of life-saving technologies but could raise Medicare spending if covered devices are expensive; no explicit cost controls are included.

Main Stakeholders Affected

• Medicare Beneficiaries: Primary beneficiaries who rely on Medicare for device coverage, gaining quicker access to innovative treatments.
• Medical Device Manufacturers: Benefit from a streamlined path to Medicare reimbursement, reducing financial risks during product launches.
• CMS and HHS: Responsible for implementation, designations, and coverage decisions, facing new procedural requirements.
• FDA: Indirectly involved, as designations rely on its priority review process; no changes to FDA authority.
• Healthcare Providers: Easier access to cover breakthrough devices, potentially improving patient care delivery.

Notable Legal, Constitutional, or Political Implications

• Legal: Establishes a mandatory coverage pathway in Medicare law, which could face challenges if seen as overriding CMS's discretion in benefit determinations. Ties closely to FDA processes, ensuring alignment between regulatory approval and reimbursement without altering FDA's role.
• Constitutional: No apparent issues; operates within Congress's authority under the Spending Clause to regulate federal programs like Medicare.
• Political: Supports bipartisan goals of fostering medical innovation and patient access, potentially influencing future healthcare policy debates on balancing speed with fiscal responsibility. Annual reporting to Congress promotes transparency and oversight.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Young, Todd [R-IN]

Cosponsors (5)

Sen. Padilla, Alex [D-CA], Sen. Barrasso, John [R-WY], Sen. Schiff, Adam B. [D-CA], Sen. Shaheen, Jeanne [D-NH], Sen. Marshall, Roger [R-KS]

Recent Actions

• 2025-05-12: Read twice and referred to the Committee on Finance.
• 2025-05-12: Introduced in Senate

Bill Versions

• Ensuring Patient Access to Critical Breakthrough Products Act of 2025 — issued 2025-05-12 — PDF (6 pages)